AOTMiT: What will the Transparency Council address at its upcoming meeting?

The agenda includes:

1. Preparation of a position paper on the evaluation of the drug Hemlibra (emicizumabum) under the drug program "Prevention of bleeding in patients with hemophilia A uncomplicated by factor VIII inhibitor" (ICD-10: D66).
2. Preparation of a position paper on the qualification of the diagnostic and therapeutic service of the biliary/pancreatic ducts with the use of a system for direct visualization as a guaranteed benefit of inpatient treatment.
3. Preparation of an opinion on the appropriateness of changes within the drug program B.128.FM "Treatment of patients with acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older" (ICD-10: E80.2).
4. Preparation of an opinion on the draft health policy program of the local government unit "Health policy program in the field of therapeutic rehabilitation of children and adolescents in the city of Zyrardow for 2026-2028".
5. Preparation of an opinion on the draft health policy program of the local government unit "Health policy program for medical rehabilitation of residents of Lubanski County for 2026-2028".
6. Preparation of an opinion on the draft health policy program of the local government unit "Health policy program Prevention of sexually transmitted diseases titled Welfare of Wroclaw students".
7. Preparation of an opinion on the draft health policy program of the local government unit "Health policy program for prevention and early detection of depression in the youth population in the Municipality of Besko for 2025-2030".
8. Preparation of an opinion on the active substance rituximab for the off-label indication under drug program B.150 "Treatment of patients with systemic lupus erythematosus (TRU, SLE)". (ICD-10: M32).
9. Preparation of an opinion on the active substance rituximab in the off-label indication under drug program B.135 "Treatment of patients with interstitial lung disease" (ICD-10: D86, J67.0-J67.9, J84.1, J84.8, J84.9, J99.0, J99.1, M34).
10. Preparation of an opinion on the active substance tocilizumab in the off-label indication under drug program B.135 "Treatment of patients with interstitial lung disease" (ICD-10: D86, J67.0-J67.9, J84.1, J84.8, J84.9, J99.0, J99.1, M34).

Source: AOTMiT